Program Highlights

CHAIR: Laila Sara Arroyo Mühr (Sweden) - Milan Stosic (Norway)

The aim of the session is to provide clinicians with a practical and clinically relevant overview of how emerging molecular and computational methods may impact cervical screening and triage in the coming years, while also discussing important limitations in interpretation and implementation.

Topics

• How to understand multi/omics studies in the context of precision screening
• How AI-based risk prediction should (and should not) be used in cervical screening
• Challenges and limitations in translating computational and molecular research into clinical practice
• Common pitfalls when interpreting molecular studies and emerging biomarkers

CHAIR: Aimée Kreimer (USA)

As the majority of the world has now adopted single dose HPV vaccination for adolescent girls, this session seeks to consider data for expanded use of single-dose HPV vaccination that will accelerate progress towards control of not just cervical cancer, but all HPV-driven cancers. The session will begin with the state of the science around single-dose HPV vaccination as well as a presentation in the gaps in knowledge. Then, the status of research studies, as well as results when available, will be presented on the following critical topics when considering expanded use for single-dose HPV vaccination: adult women using cervical and anal HPV endpoints, vulnerable women who acquire HIV, toddlers and males. The session will conclude with a presentation on global modeling work that identified the potential for increased cervical cancer inequalities worldwide without enhanced prevention efforts, as well as impact of expanded single-dose HPV vaccination of prevention of non-cervical HPV-driven cancers.

CHAIR: Marc Goodman (USA) - Margaret Madeleine (USA)

Solid organ transplant recipients experience substantially elevated rates of persistent HPV infection and HPV-associated malignancies. Chronic immunosuppression to prevent graft rejection alters viral clearance, immune surveillance, and tumor progression. As transplant survival improves and global transplantation rates increase, prevention of HPV-associated cancers in SOT recipients represents an urgent and under-addressed public health priority.

Critical gaps remain regarding optimal timing (pre- vs. post-transplant), durability of immune response, age-specific immunogenicity, and clinical effectiveness of HPV vaccination. The relationship between HPV vaccine response and post-transplantation immune status measurements is unclear and merits further exploration. Screening strategies are also inconsistently implemented across organ sites in this highly medicalized population, and evidence-based protocols for anal and oropharyngeal cancer prevention remain undefined and risks remain high.

This session integrates evidence from epidemiology, transplant immunology, HPV vaccine immunogenicity, screening strategies, and microbiome research to provide an overview of evidence-based prevention strategies and future research priorities.

At the conclusion of this session, participants will be able to:

• Describe the burden and spectrum of HPV-associated cancers in SOT recipients.
• Evaluate current evidence regarding HPV vaccine immunogenicity, safety, and optimal timing in transplant candidates and recipients.
• Understand how the microbiota influences immune responses.
• Identify screening gaps and research priorities to reduce HPV-associated cancer risk in SOT recipients and immunosuppressed populations globally.